Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Sep 26;14(5):4445–4453. doi: 10.3892/mmr.2016.5774

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Tan et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Figure 2. — Expression of molecular markers of the VSMC phenotype following various treatments. (A) The mRNA expression levels of α-sm-actin, Calponin, Osteopontin and Vimentin were determined by reverse transcription-quantitative polymerase chain reaction in T/G HA-VSMCs treated with siC, siR, siC + P, and siR + P. The mRNA expression levels were normalized against that of GAPDH. The data are presented as the mean ± standard deviation (*P<0.05 and **P<0.01 compared with the siC group.) (B) The protein expression levels of α-sm-actin, Calponin and Osteopontin were determined by western blotting analysis. The protein and mRNA expression changes were confirmed to be the same. GAPDH was used as a loading control. si, siRNA; C, control; R, Rab5a; P, PDGF; PDGF, platelet-derived growth factor; T/G HA-VSMC, human aorta-vascular smooth muscle cell line; α-sm-actin, α-smooth muscle actin.